News
NBTX
35.12
+1.44%
0.50
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX)
TipRanks · 22h ago
Nanobiotix price target raised to $30 from $3.50 at UBS
TipRanks · 22h ago
Nanobiotix reports NS Partners Europe holds 7.35% voting rights, 4.03% stake
PUBT · 3d ago
Weekly Report: what happened at NBTX last week (0420-0424)?
Weekly Report · 5d ago
Nanobiotix: Platform Expansion Potential and Risk-Adjusted NBTXR3 Valuation Support Buy Rating
TipRanks · 04/22 16:45
Nanobiotix Unveils Preclinical Data Showing Nanoprimer Boosts LNP-DNA Cancer Immunotherapy
TipRanks · 04/20 10:31
Nanobiotix Announces Positive Preclinical Data For Nanoprimer In LNP-DNA Delivery
NASDAQ · 04/20 09:40
Weekly Report: what happened at NBTX last week (0413-0417)?
Weekly Report · 04/20 09:11
Nanobiotix Nanoprimer Pre-Treatment Demonstrates Reduced Hepatic Toxicity And Improved Systemic Bioavailability For LNP-DNA Cancer Immunotherapy In Preclinical Study
Benzinga · 04/20 07:49
Nanobiotix presents mouse data on Nanoprimer boosting LNP-DNA bioavailability, reducing liver toxicity
PUBT · 04/20 06:30
NANOBIOTIX SA - NANOPRIMER PRE-TREATMENT WITH LNP-DNA SHOWS INCREASED BIOAVAILABILITY AND REDUCED TOXICITY
Reuters · 04/20 06:30
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Barchart · 04/20 01:30
Nanobiotix price target raised to EUR 34 from EUR 32 at H.C. Wainwright
TipRanks · 04/13 10:49
Weekly Report: what happened at NBTX last week (0406-0410)?
Weekly Report · 04/13 09:11
Nanobiotix Updates Share Capital and Voting Rights as of March 31, 2026
TipRanks · 04/07 20:54
Nanobiotix reports 48,517,630 issued shares, 50,143,014 exercisable voting rights
Reuters · 04/07 20:15
Voting Rights and Shares Capital of the Company
Barchart · 04/07 15:15
Weekly Report: what happened at NBTX last week (0330-0403)?
Weekly Report · 04/06 09:12
Guggenheim Maintains Buy on Nanobiotix, Raises Price Target to $36
Benzinga · 04/02 14:09
Nanobiotix price target raised to $36 from $26 at Guggenheim
TipRanks · 04/02 10:55
More
Webull provides a variety of real-time NBTX stock news. You can receive the latest news about Nanobiotix S.A. through multiple platforms. This information may help you make smarter investment decisions.
About NBTX
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.